


Anti-SLC7A5 Recombinant Antibody Products

Anti-SLC7A5 Products
-
- Derivation: Human
- Species Reactivity: Human
- Type: IgG
- Application: FC, Neut, Funcs
- Recombinant Anti-human SLC7A5 Antibody (MOB-910)
-
- Derivation: Mouse
- Species Reactivity: Human
- Type: IgG
- Application: ELISA, IF, FuncS
- Mouse Anti-SLC7A5 Recombinant Antibody (clone 98-3H3) (HPAB-0247-WJ)
-
- Species Reactivity: Human
- Type: Mouse IgG1
- Application: ELISA
- Human Anti-SLC7A5 Recombinant Antibody (clone EP3-1) (FAMAB-1260CQ)
-
- Species Reactivity: Human
- Type: Human IgG1
- Application: Activ, IP, IF
- Human Anti-SLC7A5 Antibody (clone EP3-1), mRNA (FAMAB-1260CQ-mRNA)
-
- Species Reactivity: Human
- Mouse Anti-SLC7A5 Recombinant Antibody (clone 98-3H3); scFv Fragment (HPAB-0247-WJ-S(P))
-
- Species Reactivity: Human
- Type: Mouse scFv
- Application: ELISA
- Mouse Anti-SLC7A5 Recombinant Antibody (clone 98-3H3); Fab Fragment (HPAB-0247-WJ-F(E))
-
- Species Reactivity: Human
- Type: Mouse Fab
- Application: ELISA
- Recombinant Anti-human SLC7A5 Antibody Fab Fragment (MOB-910-F(E))
-
- Derivation: Mouse
- Species Reactivity: Human
- Type: Fab
- Application: Neut, WB, FuncS
- Recombinant Anti-human SLC7A5 Antibody scFv Fragment (MOB-910-S(P))
-
- Derivation: Mouse
- Species Reactivity: Human
- Type: scFv
- Application: WB, IHC, FuncS
- Recombinant Human Anti-human SLC7A5 Antibody Fab Fragment (MHH-910-F(E))
-
- Derivation: Human
- Species Reactivity: Human
- Type: Fab
- Application: FC, Neut, Funcs
- Recombinant Human Anti-human SLC7A5 Antibody scFv Fragment (MHH-910-S(P))
-
- Derivation: Human
- Species Reactivity: Human
- Type: scFv
- Application: IF, FC, Biosensors, FuncS
-
- Species Reactivity: Mouse
- Type: Rat IgG2a, kappa
- Application: FC, IHC
- Rabbit Anti-SLC7A5 Recombinant Antibody (VS13-YC1074) (VS13-YC1074)
-
- Species Reactivity: Human
- Type: Rabbit IgG
- Application: IHC-P
- Anti-SLC7A5 Immunohistochemistry Kit (VS-0325-XY2097)
-
- Species Reactivity: Human, Mouse, Rat
- Target: SLC7A5
- Application: IHC
-
- Species Reactivity: Human
- Target: SLC7A5
- Host Animal: Human
- Application: Activ, ELISA, FC, Cell-uptake
- Anti-Mouse SLC7A5 Immunohistochemistry Kit (VS-0525-XY6696)
-
- Species Reactivity: Human, Mouse, Rat
- Target: SLC7A5
- Application: IHC
-
- Derivation: Phage display library screening
- Species Reactivity: Human
- Type: IgG
- Application: WB, IHC, IP
Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
At Creative Biolabs, we offer cutting-edge recombinant antibodies targeting SLC7A5, crucial for advancing biomedical research. Our advanced platforms guarantee that every product meets the highest standards of quality and performance. We are dedicated to accelerating scientific discovery by providing a wide range of reliable recombinant products, each designed to deliver exceptional value. In addition to our top-tier antibodies, we are committed to providing outstanding technical support, guiding researchers throughout every phase of their projects. Partnering with us means gaining not just innovative solutions but a reliable ally in your research journey.
SLC7A5: A Potential Therapeutic Target in Cancer Neurological and Metabolic Diseases
SLC7A5, or LAT1, is a key transporter for large neutral amino acids, playing an essential role in cellular metabolism. Its overexpression is commonly observed in cancer, where it supports the high nutritional demands of rapidly growing tumor cells. By facilitating amino acid uptake, SLC7A5 promotes tumor cell survival, growth, and resistance to therapies. As a result, targeting this transporter is being explored as a way to starve tumors and inhibit their progression. In neurological diseases, dysfunction of SLC7A5 can disrupt amino acid balance in the brain, contributing to conditions like Alzheimer's disease and epilepsy. Moreover, altered SLC7A5 activity is linked to metabolic disorders, where impaired amino acid transport affects normal cellular functions. Due to its involvement in these disease mechanisms, SLC7A5 is emerging as a promising therapeutic target, with potential treatments aimed at regulating its activity to improve outcomes in cancer, neurological, and metabolic diseases.
Alternative Names
Complement SLC7A5; solute carrier family 7 (amino acid transporter light chain, L system), member 5; E16; CD98; LAT1; 4F2LC; MPE16; hLAT1; D16S469E; large neutral amino acids transporter small subunit 1; 4F2 LC; 4F2 light chain; CD98 light chain; integral membrane p
Background
SLC7A5, also known as LAT1 (L - type amino acid transporter 1), is a member of the solute carrier family of membrane - bound transporters. It is a heterodimeric protein that forms a complex with 4F2hc (SLC3A2) to function as an amino acid transporter. Structurally, SLC7A5 has 12 transmembrane domains, and the heterodimeric complex is essential for its proper trafficking to the cell membrane and substrate recognition.
Metabolic proteins, Transporters
Membrane
Cell type enhanced (Basal squamous epithelial cells, Plasma cells, Microglial cells, Syncytiotrophoblasts)
Immune cell enriched (plasmacytoid DC)
Cell line enhanced (HBEC3-KT, hTCEpi, MCF7, SiHa)
Disulfide-linked heterodimer with the amino acid transport protein SLC3A2/4F2hc (PubMed:10049700, 10391915, 10574970, 11311135, 11389679, 11557028, 11564694, 12117417, 12225859, 15769744, 9751058, 25998567, 30867591). Interacts with LAPTM4B; this recruits the heterodimer formed by SLC3A2/4F2hc and SLC7A5 to lysosomes to promote leucine uptake into these organelles and is required for mTORC1 activation (PubMed:25998567).
Anti-SLC7A5 rAb Products
Our goal is to advance scientific discovery by offering high-quality anti-SLC7A5 recombinant antibodies, delivering outstanding performance and dependable technical support to assist researchers at every stage of their work.
Cat. No. | Product Name | Target Species | Host Species | Applications |
MHH-910 | Recombinant Human Anti-human SLC7A5 Antibody | Human | Human | FC; Neu; FS |
MOB-910 | Recombinant Anti-human SLC7A5 Antibody | Human | Mouse | ELISA; IF; FS |
HPAB-0247-WJ | Mouse Anti-SLC7A5 Recombinant Antibody (clone 98-3H3) | Human | Mouse | ELISA |
FAMAB-1260CQ | Human Anti-SLC7A5 Recombinant Antibody (clone EP3-1) | Human | Human | Activ; IP; IF |
Customer Reviews

Mouse Anti-SLC7A5 Recombinant Antibody (clone 98-3H3) (CAT#: HPAB-0247-WJ)

Human Anti-SLC7A5 Recombinant Antibody (clone EP3-1) (CAT#: FAMAB-1260CQ)
rAb Production
With extensive experience in recombinant antibody development and refinement, we are committed to delivering top-quality products with fast turnaround times. Our focus on superior service ensures that each antibody meets the highest standards of performance and reliability.
Featured Anti-SLC7A5 Recombinant Antibody Production Platforms
Fig.1 Milligram-scale recombinant antibody production.
Fig.2 Gram-scale recombinant antibody production.
rAb Modalities
Creative Biolabs is dedicated to offering researchers a diverse range of high-quality recombinant antibodies in various formats. Our expertise in antibody engineering allows us to support a broad spectrum of research applications. Additionally, we provide tailored antibody engineering services to accommodate the specific needs of each project.
Fig.3 Full Length Anti-SLC7A5 Recombinant Antibody Production and Modalities.
Drug Information Targeting SLC7A5
Table 1. Therapeutic approaches targeting SLC7A5 in clinical development.
Research phase | Company | Classification | Indications | Details |
Phase II | Peking University | Small Molecules | Cancer | It is a fluorine-18 radiolabeled bis-boron amino acid analogue developed by Peking University for PET imaging of brain tumors and as a potential pan-cancer agent for BNCT. |
Phase II | Quadriga BioSciences | Small Molecules |
Cancer; Triple negative breast cancer |
It is a LAT1-targeted, brain-penetrant nitrogen mustard derivative developed by Quadriga BioSciences for intravenous treatment of glioblastoma, brain metastases, and LAT1-expressing cancers. |
Phase II | Therapeia | Small Molecules |
Glioblastoma multiforme; Glioma |
It is a LAT1-targeted iodine-131 radiopharmaceutical developed by Telix Pharmaceuticals as a radiosensitizer for gliomas, including glioblastoma, in combination with external radiotherapy. |
Phase II | J-Pharma | Small Molecules | Cancer; Solid tumor | It is an L-tyrosine-derived LAT1 inhibitor developed by J-Pharma for advanced biliary tract cancers, with regional rights licensed to Ohara Pharmaceutical. |
Phase I | NARD Institute | Small Molecules | Cancer | It is an [18F]-labeled LAT1-targeting diagnostic agent for cancer developed by Osaka University and NARD Institute. |
Phase I | Igenica Biotherapeutics | Biologics |
Acute myeloid leukemia; Cancer; Lymphoma |
It is a humanized monoclonal antibody against CD98 (SLC7A5) developed by Igenica Biotherapeutics for relapsed or refractory acute myeloid leukemia. |
Phase I | Telix Pharmaceuticals | Small Molecules |
Glioblastoma multiforme; Glioma |
It is an iodine-124-labeled LAT1-targeted PET imaging agent developed by Telix Pharmaceuticals for glioblastoma multiforme diagnosis and staging. |
If you need further details about the SLC7A5 target, please don't hesitate to contact us by phone or email. Our experienced team is ready to help with any inquiries or issues you may encounter in your experiments, providing reliable support to help you achieve your research goals.